1. Search Result
Search Result
Results for "

hydrolase

" in MedChemExpress (MCE) Product Catalog:

193

Inhibitors & Agonists

5

Fluorescent Dye

11

Biochemical Assay Reagents

6

Peptides

1

Inhibitory Antibodies

19

Natural
Products

142

Recombinant Proteins

1

Isotope-Labeled Compounds

12

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153433

    Others Neurological Disease
    Serine Hydrolase inhibitor-21 (compound 8), a pyridine, is a serine hydrolase inhibitor with a Ki of 429 nM for BuChE. Serine Hydrolase inhibitor-21 has the potential for Alzheimer's disease research .
    Serine <em>Hydrolase</em> inhibitor-21
  • HY-E70042

    Endogenous Metabolite Metabolic Disease
    Nucleoside hydrolase (IAGNH) is a glycosidase. Nucleoside hydrolase (IAGNH) catalyzes the cleavage of the N-glycosidic bond in nucleosides to enable the recycling of the nucleobases and Rib .
    Nucleoside <em>hydrolase</em> (IAGNH)
  • HY-126326

    Epoxide Hydrolase Metabolic Disease
    SWE101 (compound 22 b) is a potent soluble epoxide hydrolase (sEH)-P inhibitor with IC50s of 4 μM and 2.8 μM for human and rat sEH-P, respectively. SWE101 does not inhibit neither hydrolase nor phosphatase activity of the mouse sEH .
    SWE101
  • HY-U00453

    Epoxide Hydrolase Cardiovascular Disease Metabolic Disease
    Soluble epoxide hydrolase inhibitor is an inhibitor of soluble epoxide hydrolase, and inhibits human soluble epoxide hydrolase (h-sEH) with pIC50 of 8.4, extracted from patent WO 2010096722 A1, example 57.
    Soluble epoxide <em>hydrolase</em> inhibitor
  • HY-148000

    Epoxide Hydrolase Cardiovascular Disease Inflammation/Immunology
    sEH inhibitor-6 (Compound 3g) is a soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 0.5 nM .
    sEH inhibitor-6
  • HY-103463

    FAAH MAGL Neurological Disease
    SA57 is a potent, selective FAAH inhibitor with IC50s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC50s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC50 of 850 nM), but not other brain serine hydrolases .
    SA57
  • HY-103226
    SC-57461A
    1 Publications Verification

    Aminopeptidase Inflammation/Immunology
    SC-57461A is a potent, orally active, nonpeptide, and selective inhibitor of Leukotriene A4 (LTA4) hydrolase with IC50s of 2.5 nM, 3 nM, and 23 nM for recombinant human, mouse, and rat LTA4 hydrolase, respectively .
    SC-57461A
  • HY-110138

    Others Others
    PDP-EA is a compound that increases the amidohydrolase activity of FAAH (fatty acid amide hydrolase) .
    PDP-EA
  • HY-139654

    Others Infection
    α/β-Hydrolase-IN-1 exhibits the best-in-class MICs of 50 μM (25 μg/mL) and 16 μM (8.4 μg/mL) against M. smegmatis and M. tuberculosis H37Ra, respectively.
    α/β-<em>Hydrolase</em>-IN-1
  • HY-128424

    Others Metabolic Disease
    4'-Deoxyphlorizin is an inhibitor of the glucose transport system. 4'-Deoxyphlorizi has good phlorizin hydrolase inhibitory activity with the Km value of 0.59 nM and the Ki value of 0.33 nM, respectively .
    4'-Deoxyphlorizin
  • HY-135886

    Others Others
    2-Nitrophenyl α-D-galactopyranoside, a nitrophenyl derivative, is a substrate to test for hydrolytic activity of glycosyl hydrolase .
    2-Nitrophenyl α-D-galactopyranoside
  • HY-120494

    Epoxide Hydrolase Inflammation/Immunology
    sEH inhibitor-1 (compound TCPU ) is a potent and oral active inhibitor of sEH (soluble epoxide hydrolase) with IC50s of 0.4 and 5.3 nM in human and murine, respectively .
    sEH inhibitor-1
  • HY-151621

    Epoxide Hydrolase Inflammation/Immunology
    sEH inhibitor-13 (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 0.4 μM .
    sEH inhibitor-13
  • HY-P2936

    Phospholipase Metabolic Disease
    Sphingomyelin phosphodiesterase, Streptomyces sp., a hydrolase, is involved in the sphingomyelin metabolism process. Sphingomyelin phosphodiesterase hydrolyzes the conversion of sphingomyelin to phosphocholine and ceramide. Sphingomyelin phosphodiesterase also plays an important role in cellular differentiation, various immune and inflammatory responses, and intracellular cholesterol trafficking and metabolism .
    Sphingomyelin phosphodiesterase, Streptomyces sp.
  • HY-18544

    MAGL FAAH Metabolic Disease
    AA38-3 is a serine hydrolase (SH) inhibitor. AA38-3 can inhibit three SHs, ABHD6, ABHD11, and FAAH .
    AA38-3
  • HY-10865
    LY2183240
    2 Publications Verification

    FAAH Autophagy Neurological Disease
    LY2183240 is a highly potent blocker of anandamide uptake (IC50= 270 pM; Ki=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC50 of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC50s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KIAA1363, respectively .
    LY2183240
  • HY-108570
    AUDA
    2 Publications Verification

    Epoxide Hydrolase Inflammation/Immunology
    AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively . AUDA has anti-inflammatory activity .
    AUDA
  • HY-124063

    Epoxide Hydrolase Cardiovascular Disease
    BI-1935 is a potent soluble epoxide hydrolase (sEH) inhibitor. BI-1935 can be used for the research of cardiovascular disease .
    BI-1935
  • HY-W751418

    (Z)-2-tetracos-15-enamidoethanesulfonic acid

    FAAH Neurological Disease
    N-Nervonoyl taurine ((Z)-2-tetracos-15-enamidoethanesulfonic acid) is a fatty acid-taurine conjugate derived from nervonic acid. N-Nervonoyl taurine is a substrate of fatty acid amide hydrolase (FAAH) discovered during metabolite profiling .
    N-Nervonoyl taurine
  • HY-118795

    Aminopeptidase Inflammation/Immunology
    SC-22716 is a potent, competitive, reversible inhibitor of human LTA4 hydrolase, with an IC50 of 0.20 µM. SC-22716 has potential for the research of inflammatory bowel disease (IBD) and psoriasis .
    SC-22716
  • HY-135653
    EC5026
    1 Publications Verification

    BPN-19186

    Epoxide Hydrolase Neurological Disease
    EC5026 (BPN-19186) is a first-in-class, non-opioid and orally active soluble Epoxide Hydrolase (sEH) inhibitor. EC5026 shows efficacy for inflammatory and neuropathic pain .
    EC5026
  • HY-146696

    Epoxide Hydrolase Cardiovascular Disease Neurological Disease Cancer
    mEH-IN-1 (Compound 62) is a potent microsomal epoxide hydrolase (mEH) inhibitor with the IC50 of 2.2 nM. The mEH is a mammalian α/β-fold hydrolase enzyme, expressed in almost all tissues, hydrolyzes a wide range of epoxide containing molecules. The mEH is mainly localized in the endoplasmic reticulum (ER) of eukaryotic cells. mEH-IN-1 can be used for the research of preeclampsia, hypercholanemia and cancer .
    mEH-IN-1
  • HY-113862

    Fluorescent Dye Others
    PHOME is a fluorogenic substrate for sEH. sEH can hydrolyze the epoxy ring in the PHOME substrate. PHOME can be used for fluorescent epoxide hydrolase assay (extracted from patent CN113402447A) .
    PHOME
  • HY-137298

    Aminopeptidase Inflammation/Immunology
    LTA4H-IN-1 is a potent inhibitor of leukotriene A4 hydrolase (LTA4H) extracted from patent WO2015092740A1, example 29, has an IC50 of 2 nM. LTA4H-IN-1 can be used for the research of inflammatory and autoimmune disorders .
    LTA4H-IN-1
  • HY-135659

    Bacterial Infection
    BSH-IN-1 is a potent and covalent inhibitor of gut bacterial recombinant bile salt hydrolases (BSHs) with IC50s of 108 nM and 427 nM for B. longum BSH (Gram positive) and B. theta BSH (Gram negative), respectively .
    BSH-IN-1
  • HY-113974
    trans-AUCB
    1 Publications Verification

    t-AUCB

    Epoxide Hydrolase Cancer
    trans-AUCB (t-AUCB) is a potent, orally active and selective soluble epoxide hydrolase (sEH) inhibitor with IC50s of 1.3 nM, 8 nM, 8 nM for hsEH, mouse sEH and rat sEH, respectively. trans-AUCB has anti-glioma activity .
    trans-AUCB
  • HY-W403075

    Epoxide Hydrolase Neurological Disease Inflammation/Immunology
    N-(3-Methoxybenzyl)stearamide a natural product from Lepidium meyenii (Maca), inhibits human and mouse soluble epoxide hydrolase (hsEH and msEH) with IC50s of 0.001 and <0.001 μg/nM, respectively .
    N-(3-Methoxybenzyl)stearamide
  • HY-130837

    Bacterial Infection
    JH-LPH-28, a sulfonyl piperazine analog, is a potent UDP-2,3-diacylglucosamine pyrophosphate hydrolase LpxH inhibitor. JH-LPH-28 displays outstanding antibiotic activity with a MIC value of 0.83 μg/mL .
    JH-LPH-28
  • HY-130838

    Bacterial Infection
    JH-LPH-33, a sulfonyl piperazine analog, is a potent UDP-2,3-diacylglucosamine pyrophosphate hydrolase LpxH inhibitor. JH-LPH-33 displays outstanding antibiotic activity with a MIC value of 0.66 μg/mL .
    JH-LPH-33
  • HY-130836

    Bacterial Infection
    LpxH-IN-AZ1, a sulfonyl piperazine compound, is a potent UDP-2,3-diacylglucosamine pyrophosphate hydrolase LpxH inhibitor. LpxH-IN-AZ1 is a potent inhibitor of Klebsiella pneumoniae LpxH with IC50 of 0.36 μM .
    LpxH-IN-AZ1
  • HY-125254

    Others Infection Metabolic Disease
    LEI110 is a potent, selective and cell-permeable pan-inhibitor of the HRASLS family of thiol hydrolases. LEI110 inhibits PLA2G16, HRASLS2, RARRES3 and iNAT, with pIC50 values of 7.0, 6.8, 6.8, and 7.6, respectively. LEI110 reduces cellular arachidonic acid levels and oleic acid-induced lipolysis in HepG2 cells .
    LEI110
  • HY-118960

    ATP Synthase Cardiovascular Disease
    BMS-199264 hydrochloride is an inhibitor of F1F0 ATP hydrolase (IC50=0.5 μM) without inhibitory effect on F1F0 ATP synthase. BMS-199264 hydrochloride selectively inhibits ATP decline during ischemia to reduces cardiac necrosis. BMS-199264 hydrochloride also enhances the recovery of contractile function following reperfusion .
    BMS-199264 hydrochloride
  • HY-N7062

    Takeda-25

    FAAH Neurological Disease
    JNJ-1661010 (Takeda-25) a potent and selective fatty acid amide hydrolase (FAAH) inhibitor with IC50s of 34 and 33 nM for rat FAAH and human FAAH, respectively. JNJ-1661010 can cross the blood-brain barrier and used as broad-spectrum analgesics .
    JNJ-1661010
  • HY-103462

    FAAH Metabolic Disease Inflammation/Immunology Cancer
    TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .
    TC-F2
  • HY-14380
    PF-3845
    1 Publications Verification

    FAAH Autophagy Inflammation/Immunology Cancer
    PF-3845 is a potent, selective, irreversible and orally active inhibitor of fatty acid amide hydrolase (FAAH), with a Ki of 0.23 µM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile. PF-3845 can reduce pain sensation, inflammation, and anxiety/depression without substantial effects on motility or cognition .
    PF-3845
  • HY-18638
    TCID
    1 Publications Verification

    4,5,6,7-Tetrachloroindan-1,3-dione

    Deubiquitinase Neurological Disease
    TCID (4,5,6,7-Tetrachloroindan-1,3-dione) is a potent and selective neuronal ubiquitin C-terminal hydrolase (UCH-L3) inhibitor with an IC50 of 0.6 μM . TCID diminishes glycine transporter GlyT2 ubiquitination in brainstem and spinal cord primary neurons .
    TCID
  • HY-121538

    Epoxide Hydrolase PPAR Cardiovascular Disease
    CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .
    CUDA
  • HY-145833A

    Epoxide Hydrolase Cholinesterase (ChE) Neurological Disease Cancer
    sEH/AChE-IN-4 (compound (+)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC50 values of 3.1 nM (hsEH), 1660 nM (hAChE), 179 nM (hBChE, human butyrylcholinesterase), 14.5 nM (msEH), and 102 nM (mAChE), respectively .
    sEH/AChE-IN-4
  • HY-111151

    APAU

    Epoxide Hydrolase Infection Metabolic Disease
    AR9281 (APAU) is a potent, selective and orally active soluble epoxide hydrolase (s-EH) inhibitor. AR-9281 can inhibits human sEH (HsEH) and murine sEH (MsEH) with IC50 values of 13.8 nM and 1.7 nM, respectively. AR9281 can be used for the research of inflammation, hypertension and type 2 diabetes .
    AR-9281
  • HY-145833

    Epoxide Hydrolase Cholinesterase (ChE) Neurological Disease Cancer
    sEH/AChE-IN-3 (compound (−)-15) is a potent and BBB-penetrated dual inhibitor of sEH (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC50 values of 0.4 nM (hsEH), 1.94 nM (hAChE), 615 (hBChE, human butyrylcholinesterase), 4.3 nM (msEH), and 2.61 nM (mAChE), respectively .
    sEH/AChE-IN-3
  • HY-D1726

    Deubiquitinase Cancer
    8RK59, a Bodipy probe, is a potent UCHL1 (ubiquitin C-terminal hydrolase L1) inhibitor, with an IC50 close to 1 μM. 8RK59 could penetrate and label living cells. BodipyFL-alkyne is coupled to the azide of 8RK64 (HY-148254) using copper(I)-mediated click chemistry, resulting in compound 8RK59 .
    8RK59
  • HY-163401

    Epoxide Hydrolase Cancer
    Epoxykynin is a potent epoxide hydrolase (sEH) inhibitor .
    Epoxykynin
  • HY-W027340
    ARM1
    1 Publications Verification

    4BSA

    Aminopeptidase Epoxide Hydrolase Cancer
    ARM1 (4BSA) is a potent aminopeptidase and epoxide hydrolase inhibitor. ARM1 shows aminopeptidase inhibitory activity with an IC50 7.61 µM and epoxide hydrolase inhibitory activity with an IC50 12.4 µM .
    ARM1
  • HY-B2117

    Epoxide Hydrolase HSV Infection Neurological Disease
    Valpromide is an amide derivative of valproic acid and inhibits human epoxide hydrolase.
    Valpromide
  • HY-120300

    Cannabinoid Receptor Metabolic Disease
    UCM710 is an endocannabinoid (eCB) hydrolysis inhibitor that increases the levels of N-arachidonoyl ethanolamine and 2-arachidonoylglycerol in neurons. UCM710 inhibits fatty acid amide hydrolase and α/β-hydrolase domain 6, but not monoacylglycerol lipase .
    UCM710
  • HY-U00240

    FAAH Autophagy Neurological Disease
    SA72 is a highly selective fatty acid amide hydrolase (FAAH) inhibitor.
    SA72
  • HY-101457

    JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC50 of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL) .
    JZP-430
  • HY-P990037

    CD38 Cancer
    Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity .
    Erzotabart
  • HY-152251

    Cannabinoid Receptor FAAH Inflammation/Immunology
    CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with Kis of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .
    CB2R/FAAH modulator-1
  • HY-110148

    Others Metabolic Disease
    WWL113 is a selective and orally active Ces3 and Ces1f inhibitor, with IC50 values of 120 nM and 100 nM for Ces3 and Ces1f, respectively. WWL113 appears to show excellent selectivity for the 60-kDa serine hydrolase (or hydrolases) .
    WWL113

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: